QPS, LLC has acquired majority interest in JSW Life Sciences GmbH, a provider of preclinical and Phase II–IV drug development services. The unit will be renamed QPS JSW.   JSW is a full service CRO and specializes in CNS diseases including Alzheimer’s, Parkinson’s, Huntington’s, stroke, depression, psychosis and schizophrenia. JSW also has capabilities in preclinical efficacy studies including in vitro molecular and cellular analysis, as well as experience and access to unique ...